Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 3
1998 3
1999 6
2000 6
2001 4
2002 13
2003 11
2004 12
2005 6
2006 13
2007 11
2008 14
2009 13
2010 23
2011 31
2012 38
2013 34
2014 23
2015 26
2016 31
2017 44
2018 26
2019 42
2020 39
2021 34
2022 45
2023 39
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

563 results

Results by year

Filters applied: . Clear all
Page 1
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Among authors: bertucci f. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Free article. Clinical Trial.
An integrated tumor, immune and microbiome atlas of colon cancer.
Roelands J, Kuppen PJK, Ahmed EI, Mall R, Masoodi T, Singh P, Monaco G, Raynaud C, de Miranda NFCC, Ferraro L, Carneiro-Lobo TC, Syed N, Rawat A, Awad A, Decock J, Mifsud W, Miller LD, Sherif S, Mohamed MG, Rinchai D, Van den Eynde M, Sayaman RW, Ziv E, Bertucci F, Petkar MA, Lorenz S, Mathew LS, Wang K, Murugesan S, Chaussabel D, Vahrmeijer AL, Wang E, Ceccarelli A, Fakhro KA, Zoppoli G, Ballestrero A, Tollenaar RAEM, Marincola FM, Galon J, Khodor SA, Ceccarelli M, Hendrickx W, Bedognetti D. Roelands J, et al. Among authors: bertucci f. Nat Med. 2023 May;29(5):1273-1286. doi: 10.1038/s41591-023-02324-5. Epub 2023 May 19. Nat Med. 2023. PMID: 37202560 Free PMC article.
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, Guille A, Carbuccia N, Farina A, Agavnian E, Chaffanet M, Gonçalves A, Charafe-Jauffret E, Mamessier E, Birnbaum D, Bertucci F, Lopez M. Cabaud O, et al. Among authors: bertucci f. Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013. Mol Cancer Ther. 2022. PMID: 35534238
Genomic characterization of metastatic breast cancers.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Bertucci F, et al. Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Nature. 2019. PMID: 31118521
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, Guegan JP, Rey C, Sautès-Fridman C, Bougoüin A, Cantarel C, Kind M, Spalato M, Dadone-Montaudie B, Le Loarer F, Blay JY, Fridman WH. Italiano A, et al. Among authors: bertucci f. Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26. Nat Med. 2022. PMID: 35618839 Clinical Trial.
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D. Fattori S, et al. Among authors: bertucci f. Cancer Res. 2023 Sep 15;83(18):3026-3044. doi: 10.1158/0008-5472.CAN-23-0613. Cancer Res. 2023. PMID: 37379438 Free PMC article.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Mosele F, et al. Among authors: bertucci f. Ann Oncol. 2020 Mar;31(3):377-386. doi: 10.1016/j.annonc.2019.11.006. Epub 2020 Jan 24. Ann Oncol. 2020. PMID: 32067679 Free article.
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. Wang X, et al. Among authors: bertucci f. Sci Adv. 2022 Dec 16;8(50):eabn7983. doi: 10.1126/sciadv.abn7983. Epub 2022 Dec 16. Sci Adv. 2022. PMID: 36525493 Free PMC article.
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu KD, Huang S, Bertucci F, Jiang YZ, Shao ZM; AME Breast Cancer Collaborative Group. Xiao Y, et al. Among authors: bertucci f. Clin Cancer Res. 2019 Aug 15;25(16):5002-5014. doi: 10.1158/1078-0432.CCR-18-3524. Epub 2019 Mar 5. Clin Cancer Res. 2019. PMID: 30837276
563 results